Treatment of severe COVID-19: an evolving paradigm

References

• Brault A, Néré R, Prados J, et al., Cellulosic copper nanoparticles and a hydrogen peroxide-based disinfectant trigger rapid inactivation of pseudoviral particles expressing the Spike protein of SARS-CoV-2, SARS-CoV and MERS-CoV. Metallomics. 2022;14(7): mfac044.
   PubMed Web of Science ®Google Scholar
• Merad M, Blish CA, Sallusto F, et al. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122–1127.
   PubMed Web of Science ®Google Scholar
• Witkowski M, Tizian C, Ferreira-Gomes M, et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600(7888):295–301.
   PubMed Web of Science ®Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635–641.
   PubMed Web of Science ®Google Scholar
• Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135–1140.
   PubMed Web of Science ®Google Scholar
• Tsai A, Diawara O, Nahass RG, et al. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep. 2020;10(1):19131.
   PubMed Web of Science ®Google Scholar
• Russo G, Solimini A, Zuccalà P, et al. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: a retrospective cohort study. PLoS One. 2021;16(9):e0257376.
   PubMed Web of Science ®Google Scholar
• Mahroum N, Watad A, Bridgewood C, et al. Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the pandemic. Int J Environ Res Public Health. 2021;18(17):9149.
   PubMed Web of Science ®Google Scholar
• Aomar-Millán IF, Salvatierra J, Callejas-Rubio JL, et al. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment. Reumatol Clin. 2022. DOI:10.1016/j.reuma.2022.01.003
   Web of Science ®Google Scholar
• Yang M, Lin C, Wang Y, et al. Cytokine storm promoting T cell exhaustion in severe COVID-19 revealed by single cell sequencing data analysis. Precis Clin Med. 2022;5(2):bac014.
   Google Scholar
• Zimmermann P, Uka A, Buettcher M, et al. Neonates with SARS-CoV-2 infection: spectrum of disease from a prospective nationwide observational cohort study. Swiss Med Wkly. 2022;152:w30185.
   PubMed Web of Science ®Google Scholar
• Zama D, Baccelli F, Colombini A, et al. Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Group of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP). Ann Hematol. 2022;101(8):1843–1851.
   PubMed Web of Science ®Google Scholar
• Wong G, Rowlandson M, Sabanayagam D, et al. COVID-19 infection with the omicron SARS-CoV-2 variant in a cohort of kidney and kidney pancreas transplant recipients: clinical features, risk factors, and outcomes. Transplantation. 2022;106(9):1860–1866.
   PubMed Web of Science ®Google Scholar
• Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–2460.
   PubMed Web of Science ®Google Scholar
• Ali ET, Sajid Jabbar A, Al Ali HS, et al. Extensive study on hematological, immunological, inflammatory markers, and biochemical profile to identify the risk factors in COVID-19 patients. Int J Inflam. 2022;2022:5735546.
   PubMed Web of Science ®Google Scholar
• Allwood BW, Koegelenberg CF, Ngah VD, et al. Predicting COVID-19 outcomes from clinical and laboratory parameters in an intensive care facility during the second wave of the pandemic in South Africa. IJID Reg. 2022; 3: 242–247.
   PubMedGoogle Scholar
• Arbel Y, Fialkoff C, Kerner A, et al. Can obesity prevalence explain COVID-19 Indicators (cases, mortality, and recovery)? A comparative study in OECD Countries. J Obes. 2022;2022:4320120.
   PubMed Web of Science ®Google Scholar
• Asrie F, Tekle E, Gelaw Y, et al. Baseline thrombocytopenia and disease severity among COVID-19 patients, tibebe ghion specialized hospital COVID-19 treatment center, Northwest Ethiopia. J Blood Med. 2022;13:315–325.
   PubMed Web of Science ®Google Scholar
• He X, Cheng X, Feng X, et al. Clinical symptom differences between mild and severe COVID-19 patients in china: a meta-analysis. Front Public Health. 2020;8:561264.
   PubMed Web of Science ®Google Scholar
• Xiao M, Hou M, Liu X, et al. Clinical characteristics of 71 patients with coronavirus disease 2019. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020;45(7):790–796.
   PubMedGoogle Scholar
• Wright BJ, Tideman S, Diaz GA, et al. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respir Med. 2022;10(6):557–565.
   PubMed Web of Science ®Google Scholar
• Whittington MD, Pearson SD, Rind DM, et al. The cost-effectiveness of remdesivir for hospitalized patients with COVID-19. Value Health. 2022;25(5):744–750.
   PubMed Web of Science ®Google Scholar
• Vallianou NG, Tsilingiris D, Christodoulatos GS, et al., Anti-viral treatment for SARS-CoV-2 infection: a race against time amidst the ongoing pandemic. 2021;Metabol Open. 10:100096.
   PubMedGoogle Scholar
• Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically Ill patients with covid-19. N Engl J Med. 2021;385(9):777–789.
   PubMed Web of Science ®Google Scholar
• Donato AA. In critically ill patients with COVID-19, therapeutic anticoagulation did not increase organ support-free days. Ann Intern Med. 2021;174(12):JC135.
   PubMed Web of Science ®Google Scholar
• Kumar A, Dey AD, Behl T, et al. Exploring the multifocal therapeutic approaches in COVID-19: a ray of hope. Int Immunopharmacol. 2021;90:107156.
   PubMed Web of Science ®Google Scholar
• Behl T, Kaur I, Bungau S, et al. The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. Life Sci. 2020;257:118075.
   PubMed Web of Science ®Google Scholar
• Congly SE, Varughese RA, Brown CE, et al. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep. 2021;11(1):17787.
   PubMed Web of Science ®Google Scholar
• Conway SE, Healy BC, Zurawski J, et al. COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders. Mult Scler Relat Disord. 2022;63:103946.
   PubMedGoogle Scholar
• Abdullah A, Neurath MF, Atreya R. Mild COVID-19 symptoms in an infliximab-treated ulcerative colitis patient: can ongoing anti-TNF therapy protect against the viral hyperinflammatory response and avoid aggravated outcomes? Visc Med. 2020;36(4):338–342.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang HH, et al., An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10): 1636–1643.
   PubMed Web of Science ®Google Scholar
• Alex R, Gulam SM, Kumar K. Real-life use of tocilizumab in the treatment of severe COVID-19 pneumonia. Adv Virol. 2022;2022:7060466.
   PubMed Web of Science ®Google Scholar
• Amin S, Rahim F, Bahadur S, et al. The effect of tocilizumab on inflammatory markers in survivors and non-survivors of severe COVID-19. J Coll Physicians Surg Pak. 2021;31(1):S7–S10.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar
• Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:84.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Alazawi W, Kanoni S. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;385(12):1147.
   PubMed Web of Science ®Google Scholar
• Udwadia Z, Malu KN, Tripathi R. The case against tocilizumab. J Assoc Physicians India. 2021;69(4):11–12.
   PubMedGoogle Scholar
• Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645.
   PubMed Web of Science ®Google Scholar
• Dobosh B, Zandi K, Giraldo DM, et al. Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes. Cell Rep. 2022;39(11):110945.
   PubMed Web of Science ®Google Scholar
• Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;385(5):406–415.
   PubMed Web of Science ®Google Scholar
• Li W, Wang W, Zhong L, et al. Janus kinase inhibitors in the treatment of type i interferonopathies: a case series from a single center in China. Front Immunol. 2022;13:825367.
   PubMed Web of Science ®Google Scholar
• Murphy MJ, Gruenstein D, Wang A, et al. Treatment of persistent erythema multiforme with janus kinase inhibition and the role of interferon gamma and interleukin 15 in its pathogenesis. JAMA Dermatol. 2021;157(12):1477–1482.
   PubMed Web of Science ®Google Scholar
• Joyo Y, Kawaguchi Y, Yonezu H, et al. The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes. Immunol Res. 2022;70(2):208–215.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Treatment strategies of COVID-19: a rheumatology perspective. Eur J Intern Med. 2022;102:17–23.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al., COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4): 400–402.
   PubMed Web of Science ®Google Scholar
• Kramer A, Prinz C, Fichtner F, et al. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. 2022;6:CD015209.
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81(2):318–356.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020;81(4):647–679.
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Saunders JL, Davis MD. 2020 year in review: pharmacologic treatments for COVID-19. Respir Care. 2021;66(7):1167–1172.
   PubMed Web of Science ®Google Scholar
• Shirato K, Yano T, Senba S, et al. Detection of middle east respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Virol J. 2014;11(1):139.
   PubMedGoogle Scholar
• O’Halloran J, Kedar E, Anstrom KJ, et al. Infliximab for treatment of adults hospitalized with moderate or severe covid-19. medRxiv. 2022. doi:10.1101/2022.09.22.22280245
   Google Scholar
• Ko ER, Anstrom KJ, Panettieri RA, et al. Abatacept for treatment of adults hospitalized with moderate or SEvere covid-19. medRxiv. 2022. doi:10.1101/2022.09.22.22280245
   Google Scholar